Dongyang Pharmaceutical announced that the Tokugu insulin injection developed independently by the company was officially approved for marketing by the State Drug Administration, covering the two specifications of refills and pre-filled injection pens. This drug is a fourth-generation long-acting basic insulin analog with a half-life of about 25 hours and a duration of action of more than 42 hours. After this approval, the number of insulin products approved by the company in the Chinese market has increased to 6, creating a full range of product matrices covering the second to fourth generations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.